RESERPINE

US Previously Marketed

First approved in 1954

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C33H40N2O9
Molecular Weight	608.6787
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]4([H])N(CCC5=C4NC6=C5C=CC(OC)=C6)C2

InChI

InChIKey=QEVHRUUCFGRFIF-MDEJGZGSSA-N

InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1

HIDE SMILES / InChI

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462 | https://www.ncbi.nlm.nih.gov/pubmed/15529229 | https://www.ncbi.nlm.nih.gov/pubmed/23831411

Reserpine is an alkaloid, isolated from the Rauwolfia serpentina plant and developed by Ciba pharma. Reserpine was approved by FDA for the treatment of hypertension and psychotic disorders. The drug exerts its effect by blocking two vesicular monoamine transporters, VMAT1 and VMAT2. The blockade results in vesicles that lose their ability to store neurotransmitter molecules. Neurotransmitters, thus retained in cytosol, are then neutralized by MAO.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vesicular amine transporter 1 6 Target ID: CHEMBL1838 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23831411	Blocker 530		160.0 nM [IC50]
Synaptic vesicular amine transporter 53 Target ID: CHEMBL1893 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23831411	Blocker 530		350.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 546 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462	Primary		Approved 8307	RESERPINE Approved Use Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication. Launch Date -4.66300797E11
Agitated psychotic states 6 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462	Palliative		Approved 8307	RESERPINE Approved Use Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication. Launch Date -4.66300797E11

C_max

Value	Dose	Co-administered	Analyte	Population
0.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30465727	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:		RESERPINE plasma	Equus caballus population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
4.8 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30465727	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:		RESERPINE plasma	Equus caballus population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
23.6 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30465727	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:		RESERPINE plasma	Equus caballus population: HEALTHY age: ADULT sex: MALE food status: FED

Doses

Dose	Population	Adverse events
0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	Disc. AE: Drowsiness, Light headedness... AEs leading to discontinuation/dose reduction: Drowsiness (1 patient) Light headedness (light, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	Disc. AE: Upper abdominal pain, Postural hypotension... AEs leading to discontinuation/dose reduction: Upper abdominal pain (1 patient) Postural hypotension (1 patient) Electrocardiogram abnormal (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17628352

AEs

AE	Significance	Dose	Population
Drowsiness	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Light headedness	light, 1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Electrocardiogram abnormal	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Postural hypotension	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Upper abdominal pain	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1532 activator 77	inhibitor 1695	inhibitor 1789	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1401 BSEP 392 BCRP 678 MRP2 363 OATP1B1 770 OATP1B3 691 OATP2B1 121 CYP1A2 1463 CYP2C19 1410 CYP2A6 670 CYP2E1 846 Kv1.3 16 MRP3 156 MRP4 202	P-gp 1491	P-gp 252 CYP3A4/5 112

Drug as perpetrator

Target	Modality	Activity
CYP3A4 1857	activator 208 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNzcyIn19	no [Activation >3.9811 uM]
CYP2A6 702	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc3MiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 929	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc3MiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP1A2 1620	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	no
CYP2C9 1747	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	no
OATP1B3 700	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	unlikely [Inhibition 20 uM]
MRP3 206	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	weak [IC50 133 uM]
MRP4 235	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	weak [IC50 133 uM]
Kv1.3 31	inhibitor 3185 Sources: https://www.sciencedirect.com/science/article/pii/S0041008X11000706	weak [IC50 58 uM]
BSEP 393	inhibitor 3185 Sources: http://transportal.compbio.ucsf.edu/compounds/reserpine/, https://pubmed.ncbi.nlm.nih.gov/19520776/	yes [IC50 2.8 uM]
CYP3A4 1857	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11743742/, https://pubmed.ncbi.nlm.nih.gov/24396142/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNzcyIn19	yes [IC50 20.4 uM]
BCRP 751	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/31571164/, https://pubmed.ncbi.nlm.nih.gov/17430633/, http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50017712, https://pubmed.ncbi.nlm.nih.gov/23956101/	yes [IC50 26.3 uM]
CYP2C19 1484	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	yes [IC50 <0.03 uM]
CYP2D6 1826	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	yes [IC50 <0.2 uM]
OATP1B1 785	inhibitor 3185 Sources: https://go.drugbank.com/drugs/DB00206, https://pubmed.ncbi.nlm.nih.gov/22541068/	yes [Inhibition 20 uM]
OATP2B1 124	inhibitor 3185 Sources: https://go.drugbank.com/drugs/DB00206, https://pubmed.ncbi.nlm.nih.gov/22541068/	yes [Inhibition 20 uM]
P-gp 1588	inhibitor 3185 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000050555, https://pubmed.ncbi.nlm.nih.gov/10080959/, http://transportal.compbio.ucsf.edu/compounds/reserpine/, https://pubmed.ncbi.nlm.nih.gov/12134945/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0MzAyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc3MiJ9fQ%3D%3D	yes [Ki 1.38 uM]
MRP2 452	inhibitor 3185 Sources: http://transportal.compbio.ucsf.edu/compounds/reserpine/,https://go.drugbank.com/drugs/DB00206, https://pubmed.ncbi.nlm.nih.gov/12134946/, https://pubmed.ncbi.nlm.nih.gov/23956101/, https://www.genome.jp/kegg/drug/br08309.html, https://pubmed.ncbi.nlm.nih.gov/18457386/	yes [Ki 295 uM]
CYP3A4/5 314	inducer 1515 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000050555, https://pubmed.ncbi.nlm.nih.gov/8632764/	yes
P-gp 1588	inducer 1515 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000050555, https://pubmed.ncbi.nlm.nih.gov/8632764/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1491	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/31571164/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://www.sciencedirect.com/science/article/pii/S0041008X11000706

PubMed

Title	Date	PubMed
Pharmacological analysis of a new anorexic substance: 5-hydroxy-5(4'-chlorophenyl)-2, 3-dihydro-5H-imidazo-(2, 1-a) isoindole (Mazindol).	1975 Apr	1171662
Antagonistic effect of cyproheptadine on neuroleptic-induced catalepsy.	1975 Jan-Feb	1168927
[Behavior pharmacology of maprotiline, a new antidepressant].	1975 Nov	1240830
Transient global amnesia associated with cardiac arrhythmia and digitalis intoxication.	1975 Sep-Oct	1179459
On the anticataleptic action of cyproheptadine.	1976 Aug	1033567
Antidepressant effect of an ethanolic extract of the leaves of Cissampelos sympodialis in rats and mice.	1998 Dec	10030729
Reserpine modulates serotonin transporter mRNA levels in the rat brain.	1999	10027743
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.	1999 Dec	10602339
The role of the sympathetic nervous system in the regulation of leptin synthesis in C57BL/6 mice.	1999 Feb 12	10050748
Modulation of gastrin processing by vesicular monoamine transporter type 1 (VMAT1) in rat gastrin cells.	1999 Jun 1	10332097
The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat.	2000 Feb	10711353
Brain alpha(2)-adrenoceptors in monoamine-depleted rats: increased receptor density, G coupling proteins, receptor turnover and receptor mRNA.	2001 Apr	11264240
Blood pressure-independent effect of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats.	2001 Aug	11518857
A sensitive method for the determination of gemfibrozil in human plasma samples by RP-LC.	2001 Aug	11451637
Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography.	2001 Aug 5	11499630
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.	2001 Feb 13	11172060
Determination of vitamin B(6) in cooked sausages.	2001 Jan	11170557
Separation of the insecticidal pyrethrin esters by capillary electrochromatography.	2001 Jan 5	11206800
Liquid chromatographic method with electrochemical detection for determination of cisapride in serum.	2001 Jan-Feb	11234857
Determination of famotidine in low-volume human plasma by normal-phase liquid chromatography/tandem mass spectrometry.	2001 Jul	11473396
Analysis of phenolic constituents of biological interest in red wines by high-performance liquid chromatography.	2001 Jul 13	11486883
Direct analysis of urinary trans,trans-muconic acid by coupled column liquid chromatography and spectrophotometric ultraviolet detection: method applicability to human urine.	2001 Jul 15	11486840
Application of conventional UV, photodiode array (PDA) and fluorescence (FL) detection to analysis of phenolic acids in plant material and pharmaceutical preparations.	2001 Mar	11248502
Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry.	2001 Mar 5	11254202
Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.	2001 May	11318962
Determination of 3'-azido-2',3'-dideoxyuridine in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography.	2001 May 5	11393701
Determination of aliphatic amines in water by liquid chromatography using solid-phase extraction cartridges for preconcentration and derivatization.	2001 Oct	11693606
Rapid high-performance liquid chromatographic method for the separation of hydroxylated testosterone metabolites.	2001 Sep 5	11530987
Behavioral effects of MK-801 on reserpine-treated mice.	2002 Apr	11999899
Temperature effect on peak width and column efficiency in subcritical water chromatography.	2002 Feb	11881703
Direct-injection HPLC assay for the determination of a new carbapenem antibiotic in human plasma and urine.	2002 Feb 1	11814717
Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography.	2002 Feb 5	11863286
Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice.	2002 Jan-Feb	11980384
Determination of L-sesamin and L-asarinin in Zanthoxylum(Roxb.) DC. by high performance liquid chromatography.	2002 Jul	12376305
Determination of terbutaline sulfate and its degradation products in pharmaceutical formulations using LC.	2002 Jul 31	12093527
Development and optimization of a reversed-phase high-performance liquid chromatographic method for the determination of piperacillin and tazobactam in tazocin injectable powder.	2002 Jul 31	12093510
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].	2002 May	12774329
LC-MS/MS determination of a farnesyl transferase inhibitor in human plasma and urine.	2002 Nov 7	12408906
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.	2002 Oct	12235267
Development and substantiation of a liquid chromatographic method for monitoring organic reactions involved in synthesis of 4-methoxyphenylacetic acid.	2002 Oct 4	12416886
The physiology of overwintering in a turtle that occupies multiple habitats, the common snapping turtle (Chelydra serpentina).	2002 Sep-Oct	12529844
Determination of peptides and amino acids from wool and beer with sensitive fluorescent reagent 2-(9-carbazole)-ethyl chloroformate by reverse phase high-performance liquid chromotography and liquid chromotography mass spectrometry.	2003 Feb 1	12576053
Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.	2003 Feb 10	12569393
Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line.	2003 Jan 14	12525265
Analysis of flecainide and two metabolites in biological specimens by HPLC: application to a fatal intoxication.	2003 Jan-Feb	12587684
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.	2003 Jun	12711835

Patents

Sample Use Guides

In Vivo Use Guide

Hypertension: In the average patient not receiving other antihypertensive agents, the usual initial dosage is 0.5 mg daily for 1 or 2 weeks. For maintenance, reduce to 0.1-0.25 mg daily. Psychiatric Disorders: the usual initial dosage is 0.5 mg daily, but may range from 0.1 mg to 1.0 mg. Adjust dosage upward or downward according to the patient's response.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

RESERPINE

Official Name

English

RESERPINE COMPONENT OF CAM-AP-ES

Common Name

English

HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE COMPONENT RESERPINE

Common Name

English

YOHIMBAN-16-CARBOXYLIC ACID, 11,17-DIMETHOXY-18-((3,4,5-TRIMETHOXYBENZOYL)OXY)-, METHYL ESTER, (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-

Common Name

English

SERPASIL

Brand Name

English

HYDRAP-ES COMPONENT RESERPINE

Common Name

English

RESERPINE COMPONENT OF SER-A-GEN

Common Name

English

RESERPINE [WHO-IP]

Common Name

English

METATENSIN COMPONENT RESERPINE

Common Name

English

RESERPINE [JAN]

Common Name

English

ENT-50146

Code

English

RESERPINE COMPONENT OF HYDROMOX R

Common Name

English

SANDRIL

Brand Name

English

RESERPINE [MI]

Common Name

English

REGROTON COMPONENT RESERPINE

Common Name

English

CAM-AP-ES COMPONENT RESERPINE

Common Name

English

RESERPINE [USP MONOGRAPH]

Common Name

English

DIUTENSEN-R COMPONENT RESERPINE

Common Name

English

RESERPINE [ORANGE BOOK]

Common Name

English

SER-A-GEN COMPONENT RESERPINE

Common Name

English

RESERPINE COMPONENT OF HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE

Common Name

English

RESERPINE [EP MONOGRAPH]

Common Name

English

RESERPINE COMPONENT OF SALUTENSIN

Common Name

English

RESERPINE [MART.]

Common Name

English

RESERPINE COMPONENT OF DIUTENSEN-R

Common Name

English

HYDROSERPINE PLUS (R-H-H) COMPONENT RESERPINE

Common Name

English

RAU-SED

Brand Name

English

RESERPINE [HSDB]

Common Name

English

NSC-237659

Code

English

RESERPINE COMPONENT OF DRALSERP

Common Name

English

RESERPINE COMPONENT OF METATENSIN

Common Name

English

RESERPINE COMPONENT OF HYDROPRES

Common Name

English

RESERPINUM [WHO-IP LATIN]

Common Name

English

RENESE-R COMPONENT RESERPINE

Common Name

English

RESERPINE COMPONENT OF SERPASIL-ESIDRIX

Common Name

English

RESERPINUM

Common Name

English

RESERPINE COMPONENT OF RENESE-R

Common Name

English

H.R.-50 COMPONENT RESERPINE

Common Name

English

RESERPINE COMPONENT OF HYDRO-RESERP

Common Name

English

RESERPINE COMPONENT OF REGROTON

Common Name

English

RESERPINE COMPONENT OF HYDRAP-ES

Common Name

English

RESERPINE [VANDF]

Common Name

English

RESERPINE COMPONENT OF DEMI-REGROTON

Common Name

English

RESERPINE COMPONENT OF SERPASIL-APRESOLINE

Common Name

English

HYDROMOX R COMPONENT RESERPINE

Common Name

English

DEMI-REGROTON COMPONENT RESERPINE

Common Name

English

SERPASIL-ESIDRIX COMPONENT RESERPINE

Common Name

English

RESERPINE [IARC]

Common Name

English

RESERPINE COMPONENT OF UNIPRES

Common Name

English

RESERPINE COMPONENT OF NAQUIVAL

Common Name

English

APOPLON

Brand Name

English

RESERPINE [USP-RS]

Common Name

English

RESERPINE COMPONENT OF H.R.-50

Common Name

English

SERPASIL-APRESOLINE COMPONENT RESERPINE

Common Name

English

HYDROPRES COMPONENT RESERPINE

Common Name

English

SERPALAN

Brand Name

English

HYDRO-RESERP COMPONENT RESERPINE

Common Name

English

RESERPINUM [HPUS]

Common Name

English

reserpine [INN]

Common Name

English

SALUTENSIN COMPONENT RESERPINE

Common Name

English

RESERPINE COMPONENT OF SER-AP-ES

Common Name

English

RESERPINE COMPONENT OF HYDROSERPINE PLUS (R-H-H)

Common Name

English

NSC-59272

Code

English

DRALSERP COMPONENT RESERPINE

Common Name

English

UNIPRES COMPONENT RESERPINE

Common Name

English

METHYL 18.BETA.-HYDROXY-11,17.ALPHA.-DIMETHOXY-3.BETA.,20.ALPHA.-YOHIMBAN-16.BETA.-CARBOXYLATE 3,4,5-TRIMETHOXYBENZOATE (ESTER).

Common Name

English

NAQUIVAL COMPONENT RESERPINE

Common Name

English

Reserpine [WHO-DD]

Common Name

English

METHYL (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-11,17-DIMETHOXY-18-((3,4,5-TRIMETHOXYBENZOYL)OXY)YOHIMBAN-16-CARBOXYLATE

Common Name

English

SER-AP-ES COMPONENT RESERPINE

Common Name

English

Classification Tree Code System Code

WHO-ATC

C02LA71